HEPLISAV-B is recommended by the CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults.
If you would like to learn more about HEPLISAV-B, please let us know and we will have a representative reach out to you. You may also call 1-84-HEPLISAV 1-844-375-4728, or go to their website heplisavbhcp.com and click on “request information” on the top right hand corner of the page to have a representative reach out to your office.
HEPLISAV-B is only available through authorized distributors including Vaccine Shoppe and Vaxserve. For a complete list, please call 1-84-HEPLISAV (1-844-375-4728).
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
References: 1. HEPLISAV-B [package insert]. Berkeley, CA: Dynavax Technologies Corporation; 2017.2. Dynavax’s HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults [news release]. Berkeley CA: Dynavax Technologies Corporation. http://investors.dynavax.com/news-releases/newsrelease-details/dynavaxs-heplisav-btm-hepatitis-b-vaccine-recombinant-adjuvanted. Accessed March 15, 2018.